Biosynthesis of purines and pyrimidines.

J. M. Buchanan,D. Wilson

DOI: https://doi.org/10.1111/j.1753-4887.1949.tb02197.x

Abstract:

What problem does this paper attempt to address?

A novel Bayesian generative approach for estimating tumor dynamics from published studies

Arya Pourzanjani,Saurabh Modi,Jamie Connarn,Xinwen Zhang,Vijay Upreti,Chih‐Wei Lin,Khamir Mehta

DOI: https://doi.org/10.1002/psp4.13163

2024-05-24

CPT Pharmacometrics & Systems Pharmacology

Abstract:Tumor growth inhibition (TGI) modeling attempts to describe the time course changes in tumor size for patients undergoing cancer therapy. TGI models present several advantages over traditional exposure–response models that are based explicitly on clinical end points and have become a popular tool in the pharmacometrics community. Unfortunately, the data required to fit TGI models, namely longitudinal tumor measurements, are sparse or often not available in literature or publicly accessible databases. On the contrary, common end points such as progression‐free survival (PFS) and objective response rate (ORR) are directly derived from longitudinal tumor measurements and are routinely published. To this end, a Bayesian generative model relating underlying tumor dynamics to summary PFS and ORR data is introduced to learn TGI model parameters using only published summary data. The parameterized model can describe the tumor dynamics, quantify treatment effect, and account for differences in the study population. The utility of this model is shown by applying it to several published studies, and learned parameters are combined to simulate an in silico trial of a novel combination therapy in a novel setting.

pharmacology & pharmacy
Experimental design considerations and statistical analyses in preclinical tumor growth inhibition studies

Vinicius Bonato,Szu‐Yu Tang,Matilda Hsieh,Yao Zhang,Shibing Deng

DOI: https://doi.org/10.1002/pst.2399

2024-06-12

Pharmaceutical Statistics

Abstract:Animal models are used in cancer pre‐clinical research to identify drug targets, select compound candidates for clinical trials, determine optimal drug dosages, identify biomarkers, and ensure compound safety. This tutorial aims to provide an overview of study design and data analysis from animal studies, focusing on tumor growth inhibition (TGI) studies used for prioritization of anticancer compounds. Some of the experimental design aspects discussed here include the selection of the appropriate biological models, the choice of endpoints to be used for the assessment of anticancer activity (tumor volumes, tumor growth rates, events, or categorical endpoints), considerations on measurement errors and potential biases related to this type of study, sample size estimation, and discussions on missing data handling. The tutorial also reviews the statistical analyses employed in TGI studies, considering both continuous endpoints collected at single time‐point and continuous endpoints collected longitudinally over multiple time‐points. Additionally, time‐to‐event analysis is discussed for studies focusing on event occurrences such as animal deaths or tumor size reaching a certain threshold. Furthermore, for TGI studies involving categorical endpoints, statistical methodology is outlined to compare outcomes among treatment groups effectively. Lastly, this tutorial also discusses analysis for assessing drug combination synergy in TGI studies, which involves combining treatments to enhance overall treatment efficacy. The tutorial also includes R sample scripts to help users to perform relevant data analysis of this topic.

pharmacology & pharmacy,statistics & probability
Below-Ground Attack by the Root Knot Nematode Meloidogyne graminicola Predisposes Rice to Blast Disease.

T. Kyndt,Henok Yimer Zemene,Ashley Haeck,R. Singh,D. De Vleesschauwer,S. Denil,T. de Meyer,M. Höfte,K. Demeestere,G. Gheysen

DOI: https://doi.org/10.1094/MPMI-11-16-0225-R

IF: 3.4218

2017-03-29

Molecular Plant-Microbe Interactions

Abstract:Magnaporthe oryzae (rice blast) and the root-knot nematode Meloidogyne graminicola are causing two of the most important pathogenic diseases jeopardizing rice production. Here, we show that root-knot nematode infestation on rice roots leads to important above-ground changes in plant immunity gene expression, which is correlated with significantly enhanced susceptibility to blast disease. A detailed metabolic analysis of oxidative stress responses and hormonal balances demonstrates that the above-ground tissues have a disturbed oxidative stress level, with accumulation of H2O2, as well as hormonal disturbances. Moreover, double infection experiments on an oxidative stress mutant and an auxin-deficient rice line indicate that the accumulation of auxin in the above-ground tissue is at least partly responsible for the blast-promoting effect of root-knot nematode infection.
Analyzing the distribution of progression-free survival for combination therapies: A study of model-based translational predictive methods in oncology

Marcus Baaz,Tim Cardilin,Mats Jirstrand

DOI: https://doi.org/10.1016/j.ejps.2024.106901

2024-12-01

Abstract:Progression-free survival (PFS) is an important clinical metric in oncology and is typically illustrated and evaluated using a survival function. The survival function is often estimated post-hoc using the Kaplan-Meier estimator but more sophisticated techniques, such as population modeling using the nonlinear mixed-effects framework, also exist and are used for predictions. However, depending on the choice of population model PFS will follow different distributions both quantitatively and qualitatively. Hence the choice of model will also affect the predictions of the survival curves. In this paper, we analyze the distribution of PFS for a frequently used tumor growth inhibition model with and without drug-resistance and highlight the translational implications of this. Moreover, we explore and compare how the PFS distribution for combination therapy differs under the hypotheses of additive and independent-drug action. Furthermore, we calibrate the model to preclinical data and use a previously calibrated clinical model to show that our analytical conclusions are applicable to real-world setting. Finally, we demonstrate that independent-drug action can effectively describe the tumor dynamics of patient-derived xenografts (PDXs) given certain drug combinations.
Brainstem Involvement in Legionnaires’ Disease

N. Morelli,E. Battaglia,P. Lattuada

DOI: https://doi.org/10.1007/s15010-006-4131-y

2006-02-01

Infection

Abstract:
Sample-size calculation for preclinical dose-response experiments using heterogeneous tumour models

Willy Ciecior,Nadja Ebert,Nathalie Borgeaud,Howard D Thames,Michael Baumann,Mechthild Krause,Steffen Löck

DOI: https://doi.org/10.1016/j.radonc.2021.02.032

Abstract:Background: In preclinical radio-oncological research, local tumour control is considered the most relevant endpoint as it reflects the inactivation of cancer stem cells. Preclinical tumour-control assays may compare dose-response curves between different radiotherapy strategies, e.g., assessing additional targeted drugs and immunotherapeutic interventions, or between different radiation modalities. To mimic the biological heterogeneity of human tumour populations and to accommodate for approaches of personalized oncology, preclinical studies are increasingly performed combining larger panels of tumour models. For designing the study protocols and to obtain reliable results, prospective sample-size planning has to be developed that accounts for such heterogeneous cohorts. Methods: A Monte-Carlo-based method was developed to estimate the sample size of a comparative 1:1 two-arm prospective tumour-control assay. Based on repeated logistic regression analysis, pre-defined dose levels, assumptions on the dose-response curves of the included tumour models and on the dose-modifying factors (DMF), the power is calculated for a given number of animals per dose group. Results: Two applications are presented: (i) For a simple tumour-control assay with the head and neck squamous cell carcinoma (HNSCC) model FaDu, 10 animals would be required for each of 7 dose levels per arm to reveal a DMF of 1.25 with a power of 0.82 without drop out (total: 140 animals). (ii) In a more complex experiment combining six different lung tumour models to a heterogeneous population, 21 animals would be required for each of 11 dose levels per arm to reveal a DMF of 1.25 with a power of 0.81 without drop out (total: 462 animals). Analyzing the heterogeneous cohort reduces the required animal number by more than 50% compared to six individual tumour-control assays. Conclusion: An approach for estimating the required animal number for comparative tumour-control assays in a heterogeneous population is presented, allowing also the inclusion of different treatments as a personalized approach in the experimental arm. The software is publicly available and can be applied to plan comparisons of sigmoidal dose-response curves based on logistic regression.
Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

Ying Yuan,Guosheng Yin

DOI: https://doi.org/10.1111/j.1467-9876.2009.00674.x

2009-01-01

Abstract:Summary In traditional phase I and II clinical trial designs, toxicity and efficacy are often modelled as binary outcomes. Such methods ignore information on when the outcome event occurs, such as experiencing toxicity or achieving cure or remission. They also have difficulty accommodating a high accrual rate under which toxicity and efficacy outcomes cannot be observed in a timely manner, and thus delay treatment assignment. To address these issues, we propose a Bayesian adaptive phase I–II design that jointly models toxicity and efficacy as time-to-event outcomes. At each decision-making time, patients who have not experienced toxicity or efficacy are naturally censored. We apply the marginal cure rate model to account explicitly for those patients who are insusceptible to efficacy owing to drug resistance. The correlation between the bivariate time-to-toxicity and time-to-efficacy outcomes is properly adjusted through the Clayton model. After screening out the excessively toxic or futile doses, we adaptively assign each new patient to the most appropriate dose on the basis of the ratio of the areas under the predicted survival curves corresponding to toxicity and efficacy. We conducted extensive simulation studies to examine the operating characteristics of the method proposed, and we illustrate the application of the method in a clinical trial in prostate cancer. Our design selects the target dose with a high probability, treats most patients at the desirable dose and potentially shortens the duration of a trial.
Abstract 5176: Tumor dynamic model-based decision support for phase Ib immunotherapy combination studies

René Bruno,Mathilde Marchand,Kenta Yoshida,Phyllis Chan,Haocheng Li,Wei Zou,Francois Mercier,Pascal Chanu,Benjamin Wu,Anthony Lee,Chunze Li,Jin Y. Jin

DOI: https://doi.org/10.1158/1538-7445.am2022-5176

IF: 11.2

2022-06-17

Cancer Research

Abstract:Background: Tumor growth inhibition (TGI)-overall survival (OS) models predict OS distributions and study outcomes (OS hazard ratio (HR)) in a number of cancers and settings (Bruno, Clin Cancer Res 2020;26:1787-95). Model-derived TGI metrics such as tumor growth rate (KG) have been considered as a promising early endpoint compared to classical response criteria (Gong J Clin Oncol 2020; doi: 10.1200/JCO.2020.38.15_suppl.9541). This work is assessing the validity of tumor growth rate estimates to inform GO/noGO decisions for Phase Ib studies. Methods: We resampled baseline characteristics and longitudinal sum of longest diameters (SLD, RECIST 1.1) from a positive Phase III study (IMpower150, Socinski, N Engl J Med 2018;378:2288-301) to mimic a Phase Ib study of 15, 30, or 40 patients per arm (atezolizumab +bevacizumab+carboplatin+paclitaxel (A+BCP) vs. BCP) with 10 months recruitment and 6 or 3 months follow-up (FU) after the last patient recruited. Effect sizes across A+BCP vs. BCP or BCP vs. BCP were calculated as geometric mean ratio (GMR) for KG, difference (d) in objective response rate (ORR), and HR for progression-free survival (PFS) and simulated OS. For this, individual KG were estimated using a bi-exponential model (Claret, Clin Cancer Res 2018;24:3292-8); ORR and PFS were estimated per RECIST 1.1, OS was simulated using a previously published TGI-OS model (Chan CPT:PSP 2021; doi.org/10.1002/psp4.12686) with 400 patients per arm bootstrapped from the 15, 30 or 40 patients of the resampled subsamples. Correct and incorrect Go decisions were based on the probability (prob) to achieve target effect sizes in A+BCP vs. BCP and BCP vs. BCP, respectively, across 500 replicated subsamples. Results: To not exceed an incorrect Go decision of 20% and for 40 patients/6 months FU, correct Go based on prob(KG GMR 0.10), prob(OS HR<0.85) and prob(PFS HR<0.70) were 83%, 69%, 67% and 58%, respectively. For 40 patients/3 months FU, 30 patients/6 or 3 months FU, the ranking did not change and prob(KG GMR<0.90) correct Go decision rate remained around 80%. Conclusions: This evaluation suggests that model-based estimates of on-treatment tumor growth rate could be used as an exploratory endpoint to inform early clinical decisions. Expansion of this work is planned in other settings e.g. single-arm studies commonly used in early oncology clinical development. Citation Format: René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, Francois Mercier, Pascal Chanu, Benjamin Wu, Anthony Lee, Chunze Li, Jin Y. Jin. Tumor dynamic model-based decision support for phase Ib immunotherapy combination studies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 5176.

oncology
Model-based meta-analysis of non-small cell lung cancer with standard of care PD-1 inhibitors and chemotherapy for early development decision making

David C. Turner,Russ Wada,Helen Zhou,Xiaowei Wang,Rik de Greef,Chandni Valiathan,Lindsey Zhang,Nancy Zhang,Mita Kuchimanchi,Tai-Tsang Chen,Marc Ballas,Sandra A. G. Visser

DOI: https://doi.org/10.1002/psp4.12917

2023-01-01

Abstract:Single-arm cohorts/trials are often used in early phase oncology programs to support preliminary clinical activity assessments for investigational products, administered alone or in combination with standard of care (SOC) agents. Benchmarking clinical activity of those combinations against other treatments, including SOC, requires indirect comparisons against external trials, which presents challenges including cross-study differences in trial populations/other factors. To facilitate such nonrandomized comparisons, we developed a comprehensive model-based meta-analysis (MBMA) framework to quantitatively adjust for factors related to efficacy in metastatic non-small cell lung cancer (mNSCLC). Data were derived from 15 published studies assessing key programmed cell death protein-1 (PD-1) inhibitors pembrolizumab (n = 8) and nivolumab (n = 7), representing current SOC in mNSCLC. In the first stage, a mixed-effects logistic regression model for overall response rate (ORR) was developed accounting for effects of various population covariates on ORR. The ORR model results indicated an odds ratio (OR) of 1.02 for squamous versus non-squamous histology and OR of 1.20 for PD-ligand 1 tumor proportion score (TPS) per every 10% increase of TPS level. Next, a nonparametric mixed-effects model for overall survival (OS) was developed with ORR/other clinical covariates as input. Subsequently, MBMA simulations of relevant hypothetical scenarios involving single-arm trial design predicted OS hazard ratios as a function of ORR with matched patient characteristics. Findings from this MBMA and derived parameter estimates can be generally applied by the reader as a framework for interpreting efficacy data from early phase trials to support ORR-based go/no-go decisions and futility rules, illustrated through examples in this report.
Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two-stage approaches

Mathilde Marchand,Antonio Gonçalves,François Mercier,Pascal Chanu,Jin Y Jin,Jérémie Guedj,René Bruno

DOI: https://doi.org/10.1002/psp4.13137

Abstract:Model-based tumor growth inhibition (TGI) metrics are increasingly used to predict overall survival (OS) data in Phase III immunotherapy clinical trials. However, there is still a lack of understanding regarding the differences between two-stage or joint modeling methods to leverage Phase I/II trial data and help early decision-making. A recent study showed that TGI metrics such as the tumor growth rate constant KG may have good operating characteristics as early endpoints. This previous study used a two-stage approach that is easy to implement and intuitive but prone to bias as it does not account for the relationship between the longitudinal and time-to-event processes. A relevant alternative is to use a joint modeling approach. In the present article, we evaluated the operating characteristics of TGI metrics using joint modeling, assuming an OS model previously developed using historical data. To that end, we used TGI and OS data from IMpower150-a study investigating atezolizumab in over 750 patients suffering from non-small cell lung cancer-to mimic randomized Phase Ib/II trials varying in terms of number of patients included (40 to 15 patients per arm) and follow-up duration (24 to 6 weeks after the last patient included). In this context, joint modeling did not outperform the two-stage approach and provided similar operating characteristics in all the investigated scenarios. Our results suggest that KG geometric mean ratio could be used to support early decision-making provided that 30 or more patients per arm are included and followed for at least 12 weeks.
Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth

Sébastien Benzekry,Clare Lamont,Afshin Beheshti,Amanda Tracz,John M.L. Ebos,Lynn Hlatky,Philip Hahnfeldt

DOI: https://doi.org/10.1371/journal.pcbi.1003800

2014-07-10

Abstract:Despite internal complexity, tumor growth kinetics follow relatively simple macroscopic laws that have been quantified by mathematical models. To resolve this further, quantitative and discriminant analyses were performed for the purpose of comparing alternative models for their abilities to describe and predict tumor growth. For this we used two in vivo experimental systems, an ectopic syngeneic tumor (Lewis lung carcinoma) and an orthotopically xenografted human breast carcinoma. The goals were threefold: to 1) determine a statistical model for description of the volume measurement error, 2) establish the descriptive power of each model, using several goodness-of-fit metrics and a study of parametric identifiability, and 3) assess the models ability to forecast future tumor growth. Nine models were compared that included the exponential, power law, Gompertz and (generalized) logistic formalisms. The Gompertz and power law provided the most parsimonious and parametrically identifiable description of the lung data, whereas the breast data were best captured by the Gompertz and exponential-linear models. The latter also exhibited the highest predictive power for the breast tumor growth curves, with excellent prediction scores (greater than 80$\%$) extending out as far as 12 days. In contrast, for the lung data, none of the models were able to achieve substantial prediction rates (greater than 70$\%$) further than the next day data point. In this context, adjunction of a priori information on the parameter distribution led to considerable improvement of predictions. These results not only have important implications for biological theories of tumor growth and the use of mathematical modeling in preclinical anti-cancer drug investigations, but also may assist in defining how mathematical models could serve as potential prognostic tools in the clinical setting.

Quantitative Methods,Tissues and Organs
Bayesian modeling for analyzing heterogeneous response in preclinical mouse tumor models

Bairu Zhang,Lukasz Magiera,Juliana Candido,Olga Muraeva,Jane Coates Ulrichsen,Jim Eyles,Elena Galvani,Natasha A. Karp

DOI: https://doi.org/10.1126/scitranslmed.adi9004

IF: 17.1

2024-10-31

Science Translational Medicine

Abstract:In anticancer research, tumor growth measured in mouse models is important for assessing treatment efficacy for a treatment to progress to human clinical trials. Statistical analysis of time-to-event tumor volume data is complex because of heterogeneity in response and welfare-related data loss. Traditional statistical methods of testing the mean difference between groups are not robust because they assume common responses across a population. Heterogeneity in response is also seen in the clinic, and consequently, the assessment of the treatment considers the diversity through classification of the individual's response using the RECIST (Response Evaluation Criteria in Solid Tumors). To provide a comparable and translatable assessment of in vivo tumor response, we developed a statistical method called INSPECT (IN vivo reSPonsE Classification of Tumors) for analyzing heterogeneous responses through Bayesian modeling. This method can classify individual tumor behaviors into the categories of nonresponder, modest responder, stable responder, and regressing responder. Using both published and simulated data, we show that INSPECT methodology is more accurate and sensitive than existing methods with respect to balancing false-negative and false-positive rates. A case study demonstrates the value of INSPECT in drug projects for supporting the translation of drug efficacy from the preclinical phase into clinical trials. We also provide a package, "INSPECTumours," that launches a web interface to enable users to conduct the analysis and generate reports.

cell biology,medicine, research & experimental
A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

Chunyan Cai,Ying Yuan,Yuan Ji

DOI: https://doi.org/10.1111/rssc.12039

2013-01-01

Abstract:SummaryTreating patients with novel biological agents is becoming a leading trend in oncology. Unlike cytotoxic agents, for which efficacy and toxicity monotonically increase with dose, biological agents may exhibit non-monotonic patterns in their dose–response relationships. Using a trial with two biological agents as an example, we propose a dose finding design to identify the biologically optimal dose combination, which is defined as the dose combination of the two agents with the highest efficacy and tolerable toxicity. A change point model is used to reflect the fact that the dose–toxicity surface of the combinational agents may plateau at higher dose levels, and a flexible logistic model is proposed to accommodate the possible non-monotonic pattern for the dose–efficacy relationship. During the trial, we continuously update the posterior estimates of toxicity and efficacy and assign patients to the most appropriate dose combination. We propose a novel dose finding algorithm to encourage sufficient exploration of untried dose combinations in the two-dimensional space. Extensive simulation studies show that the design proposed has desirable operating characteristics in identifying the biologically optimal dose combination under various patterns of dose–toxicity and dose–efficacy relationships.
Growth‐rate model predicts in vivo tumor response from in vitro data

Rocky Diegmiller,Laurent Salphati,Bruno Alicke,Timothy R. Wilson,Thomas J. Stout,Marc Hafner

DOI: https://doi.org/10.1002/psp4.12836

2022-07-04

Abstract:A major challenge in oncology drug development is to elucidate why drugs that show promising results in cancer cell lines in vitro fail in mouse studies or human trials. One of the fundamental steps toward solving this problem is to better predict how in vitro potency translates into in vivo efficacy. A common approach to infer whether a model will respond in vivo is based on in vitro half-maximal inhibitory concentration values (IC<sub>50</sub> ), but yields limited quantitative comparison between cell lines and drugs, potentially because cell division and death rates differ between cell lines and in vivo models. Other methods based either on mechanistic modeling or machine learning require molecular insights or extensive training data, limiting their use for early drug development. To address these challenges, we propose a mathematical model integrating in vitro growth rate inhibition values with pharmacokinetic parameters to estimate in vivo drug response. Upon calibration with a drug-specific factor, our model yields precise estimates of tumor growth rate inhibition for in vivo studies based on in vitro data. We then demonstrate how our model can be used to study dosing schedules and perform sensitivity analyses. In addition, it provides meaningful metrics to assess association with genotypes and guide clinical trial design. By relying on commonly collected data, our approach shows great promise for optimizing drug development, better characterizing the efficacy of novel molecules targeting proliferation, and identifying more robust biomarkers of sensitivity while limiting the number of in vivo experiments.

pharmacology & pharmacy
A mathematical model to study the effects of drugs administration on tumor growth dynamics

P. Magni,M. Simeoni,I. Poggesi,M. Rocchetti,G. De Nicolao

DOI: https://doi.org/10.1016/j.mbs.2005.12.028

IF: 3.935

2006-04-01

Mathematical Biosciences

Abstract:A mathematical model for describing the cancer growth dynamics in response to anticancer agents administration in xenograft models is discussed. The model consists of a system of ordinary differential equations involving five parameters (three for describing the untreated growth and two for describing the drug action). Tumor growth in untreated animals is modelled by an exponential growth followed by a linear growth. In treated animals, tumor growth rate is decreased by an additional factor proportional to both drug concentration and proliferating cells. The mathematical analysis conducted in this paper highlights several interesting properties of this tumor growth model. It suggests also effective strategies to design in vivo experiments in animals with potential saving of time and resources. For example, the drug concentration threshold for the tumor eradication, the delay between drug administration and tumor regression, and a time index that measures the efficacy of a treatment are derived and discussed. The model has already been employed in several drug discovery projects. Its application on a data set coming from one of these projects is discussed in this paper.

biology,mathematical & computational biology
Stochastic Model for Tumor Control Probability: Effects of Cell Cycle and (A)symmetric Proliferation

Andrew Dhawan,Kamran Kaveh,Mohammad Kohandel,Siv Sivaloganathan

DOI: https://doi.org/10.48550/arXiv.1312.7556

2013-12-30

Abstract:Estimating the required dose in radiotherapy is of crucial importance since the administrated dose should be sufficient to eradicate the tumor and at the same time should inflict minimal damage on normal cells. The probability that a given dose and schedule of ionizing radiation eradicates all the tumor cells in a given tissue is called the tumor control probability (TCP), and is often used to compare various treatment strategies used in radiation therapy. In this paper, we aim to investigate the effects of including cell-cycle phase on the TCP by analyzing a stochastic model of a tumor comprised of actively dividing cells and quiescent cells with different radiation sensitivities. We derive an exact phase-diagram for the steady-state TCP of the model and show that at high, clinically-relevant doses of radiation, the distinction between active and quiescent tumor cells (i.e. accounting for cell-cycle effects) becomes of negligible importance in terms of its effect on the TCP curve. However, for very low doses of radiation, these proportions become significant determinants of the TCP. Moreover, we use a novel numerical approach based on the method of characteristics for partial differential equations, validated by the Gillespie algorithm, to compute the TCP as a function of time. We observe that our results differ from the results in the literature using similar existing models, even though similar parameters values are used, and the reasons for this are discussed.

Quantitative Methods
A robust approach to sample size calculation in cancer immunotherapy trials with delayed treatment effect

Ting Ye,Menggang Yu

DOI: https://doi.org/10.1111/biom.12916

IF: 1.701

2018-07-10

Biometrics

Abstract:Immunotherapies are taking the center stage for cancer drug development and research. Many of these therapies, for example, immune checkpoint inhibitors, are known to have possible lag periods to achieve their full effects. Therefore, the proportional hazard assumption is violated when comparing survival curves in randomized clinical trials evaluating such therapies. Limited work exists in determining sample size to account for the lag period which is usually unknown. Assuming that the lag period is within some reasonable range, this article presents an approach to calculate sample size based on a maximin efficiency robust test. Both theoretical derivations and simulation results show the proposed approach can guarantee the desired power in worst case scenarios and often much more efficient than existing approaches. Application to a real trial design is also illustrated.

statistics & probability,mathematical & computational biology,biology
Analysis and sample size calculation within the responder stratified exponential survival model

Samuel Kilian,Johannes Krisam,Meinhard Kieser

DOI: https://doi.org/10.48550/arXiv.2205.11599

2022-05-24

Abstract:The primary endpoint in oncology is usually overall survival, where differences between therapies may only be observable after many years. To avoid withholding of a promising therapy, preliminary approval based on a surrogate endpoint is possible. The approval can be confirmed later by assessing overall survival within the same study. In these trials, the correlation between surrogate endpoint and overall survival has to be taken into account for sample size calculation and analysis. For a binary surrogate endpoint, this relation can be modeled by means of the responder stratified exponential survival (RSES) model proposed by Xia, Cui, and Yang (2014). We derive properties of the model and confidence intervals based on Maximum Likelihood estimators. Furthermore, we present an approximate and an exact test for survival difference. Type I error rate, power, and required sample size for both newly developed tests are determined exactly. These characteristics are compared to those of the logrank test. We show that the exact test performs best. The power of the logrank test is considerably lower in some situations. We conclude that the logrank test should not be used within the RSES model. The proposed method for sample size calculation works well. The interpretability of our proposed methods is discussed.

Methodology
Prediction of therapeutic response and cancer outcomes in solid tumours via in silico clinical trials.

Uzma Saddia Asghar,Matthew Griffiths,Amanzhol Kubeyev,Jordan Laurie,Andrea Giorni,Luiz A Zillmann da Silva,Prabu Sivasubramaniam,Matthew Foster,Andrew V. Biankin

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e13603

IF: 45.3

2024-05-31

Journal of Clinical Oncology

Abstract:e13603 Background: Oncology therapeutic development has high failure rates with substantial costs. Advances in technology, including molecular characterisations of cancer and computational power, provide the opportunity to better model therapeutic response for existing and emerging therapies. Methods: Concr adapted Bayesian statistical principles used by astrophysicists to effectively integrate multi-dimensional data (genomic & transcriptomic) for accurate modelling of cancer biology. Our proprietary computational framework was applied to predict clinical response and survival through construction of digital twins and in silico simulations of clinical trials. Predicted log odds ratios (LOR) were generated for drug response and compared to published data from 8 suitable historical clinical trials. Three distinct models underpin this framework: Drug Efficacy, Treatment Response & Overall Survival (OS). Three publicly available datasets were used for training: Cancer Therapeutic Response Portal ( in vitro dose-response data), Cancer Cell Line Encyclopaedia and TCGA. Results: For all 8 clinical studies, the digital twin model accurately simulated both trial arms, compared drug efficacy across arms and predicted which treatment was most active. Unblinded evaluation: Our model accurately predicted gemcitabine would have greater clinical benefit than 5-FU (LOR -0.10, P <0.0001) in metastatic pancreatic cancer. In advanced breast cancer, the model predicted docetaxel had a higher response rate than doxorubicin, and carboplatin response rates were similar to docetaxel in BRCA wild-type patients. In platinum-sensitive recurrent ovarian cancer, the model predicted cisplatin-based combination had a higher response rate than paclitaxel. Blinded evaluation: Using data for paclitaxel, the model correctly predicted that nab-paclitaxel+gemcitabine response rates were higher than gemcitabine in metastatic pancreatic cancer (predicted LOR -0.090, p = CMF, adjuvant TC > AC and adjuvant tamoxifen was superior to capecitabine. The underlying pan-tumour Overall Survival model used a Random Survival Forest approach, trained on 23 cancers with predictive accuracy of 0.78 AUC ROC and C-index 0.71. To enable cohort enrichment for drug response, the model segmented patient cohorts into treatment responder and non-responder. Using this approach, the log odds increased for drug response rate for 16 of the 19 different cancers and 14 of the different 17 drugs. Conclusions: Our digital twin model represents transformative technology for clinical trial simulation with strong potential for accelerating and de-risking clinical drug development, and utility for synthetic control arms.

oncology
Towards Treatment Effect Interpretability: A Bayesian Re-analysis of 194,129 Patient Outcomes Across 230 Oncology Trials

Alexander D. Sherry,Pavlos Msaouel,Gabrielle S. Kupferman,Timothy A. Lin,Joseph Abi Jaoude,Ramez Kouzy,Molly B. El-Alam,Roshal Patel,Alex Koong,Christine Lin,Adina H. Passy,Avital M. Miller,Esther J. Beck,C. David Fuller,Tomer Meirson,Zachary R. McCaw,Ethan B. Ludmir

DOI: https://doi.org/10.1101/2024.07.23.24310891

2024-07-24

Abstract:Most oncology trials define superiority of an experimental therapy compared to a control therapy according to frequentist significance thresholds, which are widely misinterpreted. Posterior probability distributions computed by Bayesian inference may be more intuitive measures of uncertainty, particularly for measures of clinical benefit such as the minimum clinically important difference (MCID). Here, we manually reconstructed 194,129 individual patient-level outcomes across 230 phase III, superiority-design, oncology trials. Posteriors were calculated by Markov Chain Monte Carlo sampling using standard priors. All trials interpreted as positive had probabilities > 90% for marginal benefits (HR < 1). However, 38% of positive trials had ≤ 90% probabilities of achieving the MCID (HR < 0.8), even under an enthusiastic prior. A subgroup analysis of 82 trials that led to regulatory approval showed 30% had ≤ 90% probability for meeting the MCID under an enthusiastic prior. Conversely, 24% of negative trials had > 90% probability of achieving marginal benefits, even under a skeptical prior, including 12 trials with a primary endpoint of overall survival. Lastly, a phase III oncology-specific prior from a previous work, which uses published summary statistics rather than reconstructed data to compute posteriors, validated the individual patient-level data findings. Taken together, these results suggest that Bayesian models add considerable unique interpretative value to phase III oncology trials and provide a robust solution for overcoming the discrepancies between refuting the null hypothesis and obtaining a MCID.

Oncology

Biosynthesis of purines and pyrimidines.

A novel Bayesian generative approach for estimating tumor dynamics from published studies

Experimental design considerations and statistical analyses in preclinical tumor growth inhibition studies

Below-Ground Attack by the Root Knot Nematode Meloidogyne graminicola Predisposes Rice to Blast Disease.

Analyzing the distribution of progression-free survival for combination therapies: A study of model-based translational predictive methods in oncology

Brainstem Involvement in Legionnaires’ Disease

Sample-size calculation for preclinical dose-response experiments using heterogeneous tumour models

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

Abstract 5176: Tumor dynamic model-based decision support for phase Ib immunotherapy combination studies

Model-based meta-analysis of non-small cell lung cancer with standard of care PD-1 inhibitors and chemotherapy for early development decision making

Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two-stage approaches

Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth

Bayesian modeling for analyzing heterogeneous response in preclinical mouse tumor models

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

Growth‐rate model predicts in vivo tumor response from in vitro data

A mathematical model to study the effects of drugs administration on tumor growth dynamics

Stochastic Model for Tumor Control Probability: Effects of Cell Cycle and (A)symmetric Proliferation

A robust approach to sample size calculation in cancer immunotherapy trials with delayed treatment effect

Analysis and sample size calculation within the responder stratified exponential survival model

Prediction of therapeutic response and cancer outcomes in solid tumours via in silico clinical trials.

Towards Treatment Effect Interpretability: A Bayesian Re-analysis of 194,129 Patient Outcomes Across 230 Oncology Trials